SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (1509)3/12/1998 1:39:00 AM
From: scaram(o)uche  Read Replies (2) of 1762
 
Maurice:

Sorry, don't follow this thread any longer, so just now saw your post.

I like the approach, but there is one major problem..... anti-lymphoma vaccines, based on use of the antibody produced by a given patient's malignant B cells, don't account for somatic mutation. That is, the portions of the antibody that are recognized as foreign by the patient are highly variable, and the tumor actually recurs wearing different clothing.

It's interesting that you brought it up in this thread, as Idec almost ended up sprouting lilies in an earlier life, due largely to attempts to vaccinate against lymphoma-associated "idiotypes".

I very much like the concept of antigen-pulsed dendritic cells, however. These approaches would certainly complement the anti-CD20 (and anti-CD19, etc.) efforts. I can't see them replacing them.

Slightly related.... Vical has licensed a naked vaccine approach for lymphoma idiotypes from Stanford. Same criticisms would apply, but.... I sort of feel that it would be a more straightforward method of trying to play catch up when a patient's tumor changes its coat. There are also experimental approaches to express an adjuvant within the same gene construct as the idiotype antigen.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News